Yanagihara, Y., Tanaka, A., Nagayoshi, M., Tanaka, I., Ohno, M., Itakura, A. (2022). Combined use of Letrozole, Cabergoline and GnRH antagonist Eliminates Ovarian Hyperstimulation Syndrome (OHSS) in Polycystic Ovarian Syndrome (PCOS). test, 12(3), 262-269. doi: 10.21608/ebwhj.2022.130534.1175
Yasuho Yanagihara; Atsushi Tanaka; Motoi Nagayoshi; Izumi Tanaka; Motoharu Ohno; Atsuo Itakura. "Combined use of Letrozole, Cabergoline and GnRH antagonist Eliminates Ovarian Hyperstimulation Syndrome (OHSS) in Polycystic Ovarian Syndrome (PCOS)". test, 12, 3, 2022, 262-269. doi: 10.21608/ebwhj.2022.130534.1175
Yanagihara, Y., Tanaka, A., Nagayoshi, M., Tanaka, I., Ohno, M., Itakura, A. (2022). 'Combined use of Letrozole, Cabergoline and GnRH antagonist Eliminates Ovarian Hyperstimulation Syndrome (OHSS) in Polycystic Ovarian Syndrome (PCOS)', test, 12(3), pp. 262-269. doi: 10.21608/ebwhj.2022.130534.1175
Yanagihara, Y., Tanaka, A., Nagayoshi, M., Tanaka, I., Ohno, M., Itakura, A. Combined use of Letrozole, Cabergoline and GnRH antagonist Eliminates Ovarian Hyperstimulation Syndrome (OHSS) in Polycystic Ovarian Syndrome (PCOS). test, 2022; 12(3): 262-269. doi: 10.21608/ebwhj.2022.130534.1175

Combined use of Letrozole, Cabergoline and GnRH antagonist Eliminates Ovarian Hyperstimulation Syndrome (OHSS) in Polycystic Ovarian Syndrome (PCOS)

Evidence Based Women's Health Journal
Article 4, Volume 12, Issue 3, August 2022, Pages 262-269    PDF (453.2 K)
Document Type: Original Article
DOI: 10.21608/ebwhj.2022.130534.1175
Authors
Yasuho Yanagihara1; Atsushi Tanaka* 1; Motoi Nagayoshi1; Izumi Tanaka1; Motoharu Ohno2; Atsuo Itakura3
1Obstetrics and Gynecology, Saint Mother Clinic, Kitakyushu, Japan
2Obstetrics and Gynecology, Juntendo Urayasu Hospital, Urayasu, Japan
3Obstetrics and Gynecology, Juntendo University School of Medicine, Bunkyo, Japan
Abstract
Aim: To determine if the properly timed, combined used of Letrozole, Cabergoline and GnRH antagonist eliminate the
occurrence of ovarian hyper stimulation syndrome (OHSS) in polycystic ovarian syndrome (PCOS)?
Study Design: We compared the severity of OHSS after using a new treatment with the severity of OHSS in a group of PCOS
patients who received the GnRH antagonist-GnRH agonist- based controlled ovarian stimulation (COS) in retrospective
cohort study between August 2019 and December 2021.
Materials and Methods: 53 PCOS patients received the new treatment were compared to 32 PCOS patients treated with
conventional methods. 5mg of Letrozole, 0.5mg of Cabergoline and 0.25mg of GnRH antagonist were administered from just
after the oocyte pick up (OPU) for five consecutive days.
Results: There were no significant differences in the clinical pregnancy rate, cumulative pregnancy rate and cumulative
live birth rate between the two COS. The number of days between OPU and menstruation start in the novel COS was
significantly lower than that of the conventional one (5.26+2.59 vs. 17.62+5.75). This treatment produced no incidences of OHSS, compared to 21.9% of all cases having mild OHSS with the conventional method.
Conclusion: We found that administering Letrozole, Cabergoline and GnRH antagonist for five days consecutively after
OPU effective for the complete prevention of OHSS.
Keywords
Cabergoline; letrozole; ovarian hyperstimulation syndrome; polycystic ovarian syndrome
Supplementary Files
Statistics
Article View: 336
PDF Download: 727